tiprankstipranks
Ambrx Biopharma downgraded to Neutral from Outperform at Baird
PremiumThe FlyAmbrx Biopharma downgraded to Neutral from Outperform at Baird
3M ago
Ambrx Biopharma downgraded to Market Perform from Outperform at JMP Securities
PremiumThe Fly
Ambrx Biopharma downgraded to Market Perform from Outperform at JMP Securities
4M ago
Ambrx Biopharma downgraded to Neutral from Buy at B. Riley
PremiumThe Fly
Ambrx Biopharma downgraded to Neutral from Buy at B. Riley
4M ago
Johnson & Johnson to acquire Ambrx Biopharma for $2B in cash
PremiumThe FlyJohnson & Johnson to acquire Ambrx Biopharma for $2B in cash
4M ago
Ambrx Biopharma to be acquired by Johnson & Johnson for $28.00 per share
PremiumThe Fly
Ambrx Biopharma to be acquired by Johnson & Johnson for $28.00 per share
4M ago
Ambrx Biopharma to be added to the Nasdaq Biotechnology Index
PremiumThe Fly
Ambrx Biopharma to be added to the Nasdaq Biotechnology Index
4M ago
Ambrx Biopharma price target lowered to $22 from $26 at Baird
PremiumThe FlyAmbrx Biopharma price target lowered to $22 from $26 at Baird
5M ago
Cantor biotech/biopharma analysts hold analyst/industry conference call
PremiumThe Fly
Cantor biotech/biopharma analysts hold analyst/industry conference call
5M ago
Ambrx Biopharma options imply 9.7% move in share price post-earnings
PremiumThe Fly
Ambrx Biopharma options imply 9.7% move in share price post-earnings
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100